Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sonrotoclax + zanubrutinib versus venetoclax + obinutuzumab in previously untreated chronic lymphocytic leukemia
2023-506948-17-00Phase 3Authorised
- Sponsor
- BeOne Medicines
- Start
- Apr 2024
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 19
01
Overview
Phase 3, randomised, open-label trial in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) comparing BGB-11417 + zanubrutinib with Venetoclax + obinutuzumab (2 arms). Primary endpoints: Progression-free survival and Undetectable minimal residual disease rate at first post-treatment follow-up. Planned start Apr 2024; status: authorised.
02
Drugs
sonrotoclaxzanubrutinibvenetoclaxobinutuzumab
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2023-506948-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506948-17-00.